Literature DB >> 22705278

The VHL/HIF axis in clear cell renal carcinoma.

Chuan Shen1, William G Kaelin.   

Abstract

Inactivation of the VHL tumor suppressor protein (pVHL) is a common event in clear cell renal carcinoma, which is the most common form of kidney cancer. pVHL performs many functions, including serving as the substrate recognition module of an ubiquitin ligase complex that targets the alpha subunits of the heterodimeric HIF transcription factor for proteasomal degradation. Deregulation of HIF2α appears to be a driving force in pVHL-defective clear cell renal carcinomas. In contrast, genetic and functional studies suggest that HIF1α serves as a tumor suppressor and is a likely target of the 14q deletions that are characteristic of this tumor type. Drugs that inhibit HIF2α, or its downstream targets such as VEGF, are in various stages of clinical testing. Indeed, clear cell renal carcinomas are exquisitely sensitive to VEGF deprivation and four VEGF inhibitors have now been approved for the treatment of this disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22705278      PMCID: PMC3663044          DOI: 10.1016/j.semcancer.2012.06.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  143 in total

Review 1.  A rationally designed small molecule that inhibits the HIF-1alpha-ARNT heterodimer from binding to DNA in vivo.

Authors:  Charles Vinson
Journal:  Sci STKE       Date:  2005-05-17

2.  The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Authors:  S Koochekpour; M Jeffers; P H Wang; C Gong; G A Taylor; L M Roessler; R Stearman; J R Vasselli; W G Stetler-Stevenson; W G Kaelin; W M Linehan; R D Klausner; J R Gnarra; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence.

Authors:  Anna E Burrows; Agata Smogorzewska; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

4.  Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue.

Authors:  J H Mydlo; J Michaeli; C Cordon-Cardo; A S Goldenberg; W D Heston; W R Fair
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

5.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

6.  HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.

Authors:  Kelly L Covello; James Kehler; Hongwei Yu; John D Gordan; Andrew M Arsham; Cheng-Jun Hu; Patricia A Labosky; M Celeste Simon; Brian Keith
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

7.  Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface.

Authors:  Nicholas G Nickols; Claire S Jacobs; Michelle E Farkas; Peter B Dervan
Journal:  ACS Chem Biol       Date:  2007-08-17       Impact factor: 5.100

8.  Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus.

Authors:  Yuichi Makino; Arvydas Kanopka; William J Wilson; Hirotoshi Tanaka; Lorenz Poellinger
Journal:  J Biol Chem       Date:  2002-07-15       Impact factor: 5.157

9.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

10.  Regulation of endocytosis via the oxygen-sensing pathway.

Authors:  Yi Wang; Olga Roche; Mathew S Yan; Greg Finak; Andrew J Evans; Julie L Metcalf; Bridgid E Hast; Sara C Hanna; Bill Wondergem; Kyle A Furge; Meredith S Irwin; William Y Kim; Bin T Teh; Sergio Grinstein; Morag Park; Philip A Marsden; Michael Ohh
Journal:  Nat Med       Date:  2009-03-01       Impact factor: 53.440

View more
  147 in total

1.  The Dawning of a New Day in CKD Anemia Care?

Authors:  Colin R Lenihan; Wolfgang C Winkelmayer
Journal:  J Am Soc Nephrol       Date:  2015-10-22       Impact factor: 10.121

Review 2.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 4.  The role of HIF proteins in maintaining the metabolic health of the intervertebral disc.

Authors:  Elizabeth S Silagi; Ernestina Schipani; Irving M Shapiro; Makarand V Risbud
Journal:  Nat Rev Rheumatol       Date:  2021-06-03       Impact factor: 20.543

5.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.

Authors:  Randy F Sweis; Milica Medved; Shannon Towey; Gregory S Karczmar; Aytekin Oto; Russell Z Szmulewitz; Peter H O'Donnell; Paul Fishkin; Theodore Karrison; Walter M Stadler
Journal:  Clin Genitourin Cancer       Date:  2016-08-17       Impact factor: 2.872

6.  ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.

Authors:  Camillo Porta; Silvia Chiellino
Journal:  Ann Transl Med       Date:  2016-10

7.  New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.

Authors:  Ramaprasad Srinivasan; Christopher J Ricketts; Carole Sourbier; W Marston Linehan
Journal:  Clin Cancer Res       Date:  2015-01-01       Impact factor: 12.531

Review 8.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

Review 9.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

10.  USP37 promotes deubiquitination of HIF2α in kidney cancer.

Authors:  Kai Hong; Lianxin Hu; Xijuan Liu; Jeremy M Simon; Travis S Ptacek; Xingnan Zheng; Chengheng Liao; Albert S Baldwin; Qing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.